VKTX
HEALTHCAREViking Therapeutics Inc
AI Insight
What's Moving VKTX Today?
No stock-specific AI insight has been generated for VKTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$22.96$43.15
$34.81
Fundamentals
Market Cap$3.7B
P/E Ratio—
EPS$-4.15
Dividend Yield—
Dividend / Share—
ROE-70.0%
Profit Margin—
Debt / Equity—
Trading
Volume6.2M
Avg Volume (10D)—
Shares Outstanding116.1M
VKTX News
32 articles- Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?Motley Fool·Jun 23, 2026
- 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal247 Wall St·Jun 23, 2026
- Is Viking Therapeutics Stock a No-Brainer Buy Below $35?Motley Fool·Jun 23, 2026
- Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo NordiskMotley Fool·Jun 23, 2026
- Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 YearsMotley Fool·Jun 22, 2026
- Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should KnowYahoo Finance·Jun 17, 2026
- Viking Therapeutics (VKTX) Offers Potential With VK2735 Market OpportunityYahoo Finance·Jun 17, 2026
- Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And ValuationYahoo Finance·Jun 12, 2026
- Is Viking Therapeutics Stock Going to $100?The Motley Fool·Jun 12, 2026
- Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical OfficerYahoo Finance·Jun 11, 2026
- Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowYahoo Finance·Jun 10, 2026
- Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%Motley Fool·Jun 10, 2026
- Basic earnings per share (basic EPS) of Viking Therapeutics, Inc. – XETR:1VTTradingView·Jun 6, 2026
- Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderYahoo Finance·Jun 4, 2026
- Should Viking’s VK2735 Obesity Program Advancements Require Action From Viking Therapeutics (VKTX) Investors?Yahoo Finance·Jun 3, 2026
- Bull vs. Bear: The Quick Take on Viking Therapeutics StockMotley Fool·Jun 3, 2026
- VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% UpsideStocktwits·Jun 2, 2026
- Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside DownMotley Fool·Jun 2, 2026
- Viking Therapeutics (VKTX) Misses Q1 Earnings as VK2735 R&D Surges Into Late-Stage Obesity TrialsSimply Wall Street·Jun 1, 2026
- The Smartest Growth Stocks to Buy With $2,000 Right NowThe Motley Fool·May 30, 2026
- Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?Yahoo Finance·May 29, 2026
- If Viking Therapeutics Is Acquired, Here’s Who Wins247 Wall St·May 26, 2026
- Don't Buy Viking Therapeutics Stock Until You Read ThisMotley Fool·May 26, 2026
- Is Viking Therapeutics a Top Takeover Target?The Motley Fool·May 23, 2026
- Best Weight Loss Drug Stocks to Buy in 2026The Motley Fool·May 21, 2026
- Eli Lilly Stock: Next Stop $2,000?The Motley Fool·May 18, 2026
- Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?The Motley Fool·Apr 25, 2026
- Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?The Motley Fool·Apr 17, 2026
- Viking Therapeutics to Participate at Upcoming Investor ConferencesBenzinga·Apr 10, 2026
- Where Will Viking Therapeutics Stock Be in 10 Years?The Motley Fool·Apr 3, 2026
- 1 Reason This Biotech Stock Could Triple Before Year-EndThe Motley Fool·Mar 29, 2026
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735Benzinga·Mar 26, 2026
All 32 articles loaded
Price Data
Open$31.76
Previous Close$32.37
Day High$35.90
Day Low$31.76
52 Week High$43.15
52 Week Low$22.96
52-Week Range
$22.96$43.15
$34.81
Fundamentals
Market Cap$3.7B
P/E Ratio—
EPS$-4.15
Dividend Yield—
Dividend / Share—
ROE-70.0%
Profit Margin—
Debt / Equity—
Trading
Volume6.2M
Avg Volume (10D)—
Shares Outstanding116.1M
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—